Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy-Reference-Cited by-同舟云学术

Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy

Published:2022-09-01 Issue:17-18 Volume:33 Page:923-935
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Lu-Nguyen Ngoc¹^ORCID,Malerba Alberto¹^ORCID,Antoni Pineda Marina¹,Dickson George¹,Popplewell Linda¹

Affiliation:

1. Department of Biological Sciences, Centre for Biomedical Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2021.251

Reference71 articles.

1. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample

2. Population-based incidence and prevalence of facioscapulohumeral dystrophy

3. Facioscapulohumeral Dystrophy

4. Facioscapulohumeral Muscular Dystrophy

5. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism;Cell Death & Disease;2023-11-16

2. A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice;Biomedicines;2023-08-22

3. 268th ENMC workshop - Genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): Relevance for clinical trials;Neuromuscular Disorders;2023-05

4. Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism;2023-02-02

5. Facioscapulohumeral muscular dystrophy: the road to targeted therapies;Nature Reviews Neurology;2023-01-10